Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10159895 | PMC |
| http://dx.doi.org/10.1016/j.amjmed.2022.12.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Global Analysis of Regulatory Frameworks and Drug Safety Standards in the Drug Approval Process.
Curr Drug Saf
September 2025
Department of Pharmaceutics, Jayawantrao Sawant College of Pharmacy and Research, Savitribai Phule Pune University, Pune, 411028, India.
The drug approval and review process plays a crucial role in the pharmaceutical industry, aiming to ensure that newly marketed drugs are safe, effective, and of high quality. Regulatory authorities overseeing this process, tailored to geographically distinct needs, include the U.S.
View Article and Find Full Text PDFConcomitant Osteotomy and Meniscus Centralization Should Be Considered in Selected Patients Undergoing Medial Meniscus Posterior Root Repair.
Arthroscopy
September 2025
AZBSC Orthopedics, Scottsdale, Arizona. Electronic address:
Medial meniscus posterior root tears (MMPRTs) are associated with severe biomechanical consequences (loss of hoop force transmission) that are broadly equivalent to a total meniscectomy. The resultant increase in contact pressures predisposes to high rates of advanced medial compartment arthritis at long-term follow-up. Repair of MMPRTs is associated with significantly better outcomes than partial meniscectomy or non-operative treatment (including improved patient reported outcome measures and delay or even avoidance of arthroplasty).
View Article and Find Full Text PDFPrognostic factors for incontinence-associated dermatitis (IAD): Results of an international expert survey.
J Tissue Viability
September 2025
Swedish Centre for Skin and Wound Research (SCENTR), School of Health Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Skin Integrity Research Group (SKINT), University Centre for Nursing and Midwifery, Department of Public Health and Primary Care, Faculty of Medicine a
Background: Incontinence-associated dermatitis (IAD) is a prevalent and distressing form of irritant contact dermatitis caused by prolonged exposure to urine and/or faeces. Not all incontinent individuals develop IAD, suggesting that additional prognostic factors contribute to its onset. The quality of empirical evidence supporting risk factors for IAD development is moderate to very low.
View Article and Find Full Text PDF[Prevention and management of heavy uterine bleeding in pediatric patients treated for an acute leukemia: Guidelines of the SFCE leukemia committee].
Bull Cancer
September 2025
Endocrinologie diabétologie et gynécologie pédiatrique, hôpital des Enfants, CHU de Bordeaux, Bordeaux, France.
The harmonization workshops of the leukemia committee of the Société française des cancers de l'enfant (SFCE) aim to establish practical recommendations based on the one hand, on data from the literature and international recommendations and, on the other hand, by consensus in the absence of formally proven data. Adolescent pubescent girls and young adults undergoing intensive chemotherapy treatment may present with heavy uterine bleeding (HUB). Data collected from 25 French centers showed that there was considerable heterogeneity in the management of HUB either in prophylaxis or curative strategy.
View Article and Find Full Text PDF[Acute graft-versus-host disease therapy: Which third line treatment after steroids and ruxolitinib? (SFGM-TC)].
Bull Cancer
September 2025
Service d'hématologie, département d'oncologie, hôpitaux universitaire de Genève (HUG), faculté de médecine, université de Genève, Genève, Suisse. Electronic address:
Acute graft-versus-host disease (GVHDa) is one of the leading causes of morbidity and mortality after allogeneic hematopoietic stem cell transplant (HSCT) patients. While the first-line consensus treatment has been based on systemic corticosteroid therapy for many years, ruxolitinib has recently been approved and has become the standard second-line treatment. Nevertheless, the effectiveness of ruxolitinib remains limited to 40 % of cortico-resistant patients, raising the crucial question of selecting a third-line treatment.
View Article and Find Full Text PDF